Loading...

China Biotech Services Holdings

SEHK:8037
Snowflake Description

Flawless balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
8037
SEHK
HK$1B
Market Cap
  1. Home
  2. HK
  3. Healthcare
Company description

China Biotech Services Holdings Limited, an investment holding company, provides medical laboratory testing and health check services. The last earnings update was 33 days ago. More info.


Add to Portfolio Compare Print
  • China Biotech Services Holdings has significant price volatility in the past 3 months.
8037 Share Price and Events
7 Day Returns
-0.8%
SEHK:8037
-2.8%
HK Healthcare
0.5%
HK Market
1 Year Returns
-24.4%
SEHK:8037
-25.7%
HK Healthcare
-15.9%
HK Market
8037 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
China Biotech Services Holdings (8037) -0.8% -4.5% -25.3% -24.4% 257.7% -35.2%
HK Healthcare -2.8% -6.8% -17% -25.7% -26.5% -8.8%
HK Market 0.5% -4% -8.6% -15.9% 20.6% 3%
1 Year Return vs Industry and Market
  • 8037 outperformed the Healthcare industry which returned -25.7% over the past year.
  • 8037 underperformed the Market in Hong Kong which returned -15.9% over the past year.
Price Volatility
8037
Industry
5yr Volatility vs Market

Value

 Is China Biotech Services Holdings undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for China Biotech Services Holdings. This is due to cash flow or dividend data being unavailable. The share price is HK$1.27.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for China Biotech Services Holdings's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are China Biotech Services Holdings's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
SEHK:8037 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in HKD HK$-0.07
SEHK:8037 Share Price ** SEHK (2019-06-14) in HKD HK$1.27
Hong Kong Healthcare Industry PE Ratio Median Figure of 19 Publicly-Listed Healthcare Companies 15.12x
Hong Kong Market PE Ratio Median Figure of 1,487 Publicly-Listed Companies 10.68x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of China Biotech Services Holdings.

SEHK:8037 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SEHK:8037 Share Price ÷ EPS (both in HKD)

= 1.27 ÷ -0.07

-17.43x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • China Biotech Services Holdings is loss making, we can't compare its value to the HK Healthcare industry average.
  • China Biotech Services Holdings is loss making, we can't compare the value of its earnings to the Hong Kong market.
Price based on expected Growth
Does China Biotech Services Holdings's expected growth come at a high price?
Raw Data
SEHK:8037 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -17.43x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Hong Kong Healthcare Industry PEG Ratio Median Figure of 7 Publicly-Listed Healthcare Companies 1.03x
Hong Kong Market PEG Ratio Median Figure of 466 Publicly-Listed Companies 0.76x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for China Biotech Services Holdings, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on China Biotech Services Holdings's assets?
Raw Data
SEHK:8037 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in HKD HK$0.35
SEHK:8037 Share Price * SEHK (2019-06-14) in HKD HK$1.27
Hong Kong Healthcare Industry PB Ratio Median Figure of 35 Publicly-Listed Healthcare Companies 1.68x
Hong Kong Market PB Ratio Median Figure of 2,169 Publicly-Listed Companies 0.93x
SEHK:8037 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SEHK:8037 Share Price ÷ Book Value per Share (both in HKD)

= 1.27 ÷ 0.35

3.67x

* Primary Listing of China Biotech Services Holdings.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • China Biotech Services Holdings is overvalued based on assets compared to the HK Healthcare industry average.
X
Value checks
We assess China Biotech Services Holdings's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. China Biotech Services Holdings has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is China Biotech Services Holdings expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as China Biotech Services Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
15.3%
Expected Healthcare industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is China Biotech Services Holdings expected to grow at an attractive rate?
  • Unable to compare China Biotech Services Holdings's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare China Biotech Services Holdings's earnings growth to the Hong Kong market average as no estimate data is available.
  • Unable to compare China Biotech Services Holdings's revenue growth to the Hong Kong market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
SEHK:8037 Future Growth Rates Data Sources
Data Point Source Value (per year)
Hong Kong Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 15.3%
Hong Kong Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 12.7%
Hong Kong Market Earnings Growth Rate Market Cap Weighted Average 11.2%
Hong Kong Market Revenue Growth Rate Market Cap Weighted Average 10.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
SEHK:8037 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in HKD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
SEHK:8037 Future Estimates Data
Date (Data in HKD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
SEHK:8037 Past Financials Data
Date (Data in HKD Millions) Revenue Cash Flow Net Income *
2019-03-31 67 -66
2018-12-31 70 -15 -64
2018-09-30 75 -95
2018-06-30 79 -40 -83
2018-03-31 88 -48
2017-12-31 105 -57 -63
2017-09-30 111 -48
2017-06-30 113 -11 -64
2017-03-31 104 -103
2016-12-31 87 -25 -86
2016-09-30 69 -81
2016-06-30 52 -90 -84

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if China Biotech Services Holdings is high growth as no earnings estimate data is available.
  • Unable to determine if China Biotech Services Holdings is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
SEHK:8037 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from China Biotech Services Holdings Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SEHK:8037 Future Estimates Data
Date (Data in HKD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
SEHK:8037 Past Financials Data
Date (Data in HKD Millions) EPS *
2019-03-31 -0.07
2018-12-31 -0.07
2018-09-30 -0.11
2018-06-30 -0.10
2018-03-31 -0.06
2017-12-31 -0.08
2017-09-30 -0.06
2017-06-30 -0.08
2017-03-31 -0.14
2016-12-31 -0.12
2016-09-30 -0.12
2016-06-30 -0.15

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if China Biotech Services Holdings will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine China Biotech Services Holdings's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. China Biotech Services Holdings's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. China Biotech Services Holdings's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess China Biotech Services Holdings's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Hong Kong market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Hong Kong market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
China Biotech Services Holdings has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has China Biotech Services Holdings performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare China Biotech Services Holdings's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • China Biotech Services Holdings does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare China Biotech Services Holdings's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare China Biotech Services Holdings's 1-year growth to the HK Healthcare industry average as it is not currently profitable.
Earnings and Revenue History
China Biotech Services Holdings's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from China Biotech Services Holdings Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SEHK:8037 Past Revenue, Cash Flow and Net Income Data
Date (Data in HKD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 67.33 -65.70 95.07
2018-12-31 70.30 -64.25 95.95
2018-09-30 75.49 -94.77 93.81
2018-06-30 78.85 -82.53 82.48
2018-03-31 88.19 -48.35 73.49
2017-12-31 105.14 -63.02 68.75
2017-09-30 111.28 -48.15 60.63
2017-06-30 112.54 -64.38 64.29
2017-03-31 104.10 -102.66 71.19
2016-12-31 86.57 -85.68 72.53
2016-09-30 68.85 -80.73 71.57
2016-06-30 52.21 -83.82 62.23
2016-03-31 38.72 -72.20 50.46
2015-12-31 34.13 -54.16 43.61
2015-09-30 3.01 -36.02 18.64
2015-06-30 38.23 -21.49 26.80
2015-03-31 56.49 -43.44 35.27
2014-12-31 70.11 -74.85 47.12
2014-09-30 110.63 -84.60 75.49
2014-06-30 91.98 -84.09 73.08
2014-03-31 89.14 -78.64 68.66
2013-12-31 85.30 -60.23 59.44
2013-09-30 81.45 -43.55 51.58
2013-06-30 112.92 14.66 52.20
2013-03-31 90.33 -25.60 48.30
2012-12-31 83.76 -33.98 51.43
2012-09-30 61.27 -12.79 48.16
2012-06-30 16.63 -68.68 43.95

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if China Biotech Services Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if China Biotech Services Holdings has efficiently used its assets last year compared to the HK Healthcare industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if China Biotech Services Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess China Biotech Services Holdings's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
China Biotech Services Holdings has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is China Biotech Services Holdings's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up China Biotech Services Holdings's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • China Biotech Services Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • China Biotech Services Holdings's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of China Biotech Services Holdings's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 44.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from China Biotech Services Holdings Company Filings, last reported 2 months ago.

SEHK:8037 Past Debt and Equity Data
Date (Data in HKD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 318.92 4.87 157.05
2018-12-31 318.92 4.87 157.05
2018-09-30 229.31 34.88 56.45
2018-06-30 229.31 34.88 56.45
2018-03-31 251.31 31.54 76.15
2017-12-31 251.31 31.54 76.15
2017-09-30
2017-06-30 270.71 25.37 64.61
2017-03-31 275.22 21.97 88.54
2016-12-31 275.22 21.97 88.54
2016-09-30
2016-06-30 320.01 16.05 31.18
2016-03-31 342.74 1.92 75.23
2015-12-31 342.74 1.92 75.23
2015-09-30
2015-06-30 224.91 30.39 51.54
2015-03-31 197.91 29.72 39.16
2014-12-31 197.91 29.72 39.16
2014-09-30
2014-06-30 124.52 55.75 22.02
2014-03-31 128.19 59.19 32.09
2013-12-31 128.19 59.19 32.09
2013-09-30 158.79 40.84 86.74
2013-06-30 95.38 31.68 14.79
2013-03-31 95.38 31.68 14.79
2012-12-31 106.82 27.71 104.99
2012-09-30 106.82 27.71 38.28
2012-06-30
  • China Biotech Services Holdings's level of debt (1.5%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (46.2% vs 1.5% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • China Biotech Services Holdings has sufficient cash runway for more than 3 years based on current free cash flow.
  • China Biotech Services Holdings has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -39.2% each year.
X
Financial health checks
We assess China Biotech Services Holdings's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. China Biotech Services Holdings has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is China Biotech Services Holdings's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from China Biotech Services Holdings dividends.
If you bought HK$2,000 of China Biotech Services Holdings shares you are expected to receive HK$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate China Biotech Services Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate China Biotech Services Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
SEHK:8037 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Hong Kong Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 13 Stocks 2.5%
Hong Kong Market Average Dividend Yield Market Cap Weighted Average of 966 Stocks 3.7%
Hong Kong Minimum Threshold Dividend Yield 10th Percentile 1.2%
Hong Kong Bottom 25% Dividend Yield 25th Percentile 2.1%
Hong Kong Top 25% Dividend Yield 75th Percentile 6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

SEHK:8037 Future Dividends Estimate Data
Date (Data in HK$) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as China Biotech Services Holdings has not reported any payouts.
  • Unable to verify if China Biotech Services Holdings's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of China Biotech Services Holdings's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as China Biotech Services Holdings has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess China Biotech Services Holdings's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can China Biotech Services Holdings afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. China Biotech Services Holdings has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of China Biotech Services Holdings's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • China Biotech Services Holdings has no CEO, or we have no data on them.
Management Team

Xiaolin Liu

TITLE
Co-Chairman
COMPENSATION
HK$5M
AGE
48

Anson Leung

TITLE
Compliance Officer & Executive Director
COMPENSATION
HK$3M
AGE
52
TENURE
6.1 yrs

Zheng Wang

TITLE
Executive Director
COMPENSATION
HK$3M
AGE
36

Xun He

TITLE
Executive Director
COMPENSATION
HK$192K
AGE
54

Michael Yao

TITLE
Co-Chairman of the Board
AGE
59

Miu Wong

TITLE
Company Secretary
TENURE
1.7 yrs

Sze Man Ma

TITLE
Head of Operation - DVF Group
AGE
47

Michael Wah

TITLE
Head of Quality - DVF Holdco (Cayman) Limited
AGE
61
Board of Directors Tenure

Average tenure and age of the China Biotech Services Holdings board of directors in years:

1.3
Average Tenure
48
Average Age
  • The average tenure for the China Biotech Services Holdings board of directors is less than 3 years, this suggests a new board.
Board of Directors

Xiaolin Liu

TITLE
Co-Chairman
COMPENSATION
HK$5M
AGE
48
TENURE
0.1 yrs

Anson Leung

TITLE
Compliance Officer & Executive Director
COMPENSATION
HK$3M
AGE
52
TENURE
6.1 yrs

Zheng Wang

TITLE
Executive Director
COMPENSATION
HK$3M
AGE
36
TENURE
1.8 yrs

Xun He

TITLE
Executive Director
COMPENSATION
HK$192K
AGE
54
TENURE
0.8 yrs

Michael Yao

TITLE
Co-Chairman of the Board
AGE
59
TENURE
0.1 yrs

Guoxiang Yan

TITLE
Independent Non-Executive Director
COMPENSATION
HK$120K
AGE
51
TENURE
1.8 yrs

Song Huang

TITLE
Non-Executive Director
COMPENSATION
HK$2M
AGE
36
TENURE
1.8 yrs

Qian Hongji

TITLE
Independent Non-Executive Director
COMPENSATION
HK$199K
AGE
42
TENURE
1.3 yrs

Ivan Ho

TITLE
Independent Non-Executive Director
AGE
41
TENURE
0.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (HK$) Value (HK$)
31. Oct 18 Buy Wing Yiu Yau Individual 11. Sep 18 11. Sep 18 93,820,000 HK$2.00 HK$187,639,741
31. Oct 18 Sell Xiaolin Liu Individual 11. Sep 18 11. Sep 18 -93,820,000 HK$2.00 HK$-187,639,741
17. Oct 18 Buy China Construction Bank Corporation, Asset Management Arm Company 06. Sep 18 06. Sep 18 47,600,000 HK$1.68 HK$79,968,132
X
Management checks
We assess China Biotech Services Holdings's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. China Biotech Services Holdings has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

What Are The Drivers Of China Biotech Services Holdings Limited's (HKG:8037) Risks?

If you are looking to invest in China Biotech Services Holdings Limited’s (HKG:8037), or currently own the stock, then you need to understand its beta in order to understand how it can affect the risk of your portfolio. … The second risk is market-wide, which arises from investing in the stock market. … A popular measure of market risk for a stock is its beta, and the market as a whole represents a beta value of one.

Simply Wall St -

Is China Biotech Services Holdings Limited (HKG:8037) A Financially Sound Company?

Investors are always looking for growth in small-cap stocks like China Biotech Services Holdings Limited (HKG:8037), with a market cap of HK$1.45b. … However, an important fact which most ignore is: how financially healthy is the business?

Simply Wall St -

What You Must Know About China Biotech Services Holdings Limited's (HKG:8037) Financial Strength

8037 has built up its total debt levels in the last twelve months, from HK$21.97M to HK$31.54M , which is made up of current and long term debt. … With this rise in debt, the current cash and short-term investment levels stands at HK$76.15M , ready to deploy into the business. … Risk around debt is very low for 8037, and the company also has the ability and headroom to increase debt if needed going forward.Next Steps: Although 8037’s debt level is relatively low, its cash flow levels still could not copiously cover its borrowings.

Simply Wall St -

Should You Be Holding China Biotech Services Holdings Limited (HKG:8037) Right Now?

If you are looking to invest in China Biotech Services Holdings Limited’s (SEHK:8037), or currently own the stock, then you need to understand its beta in order to understand how it can affect the risk of your portfolio. … 8037, with its market capitalisation of HK$1.46B, is a small-cap stock, which generally have higher beta than similar companies of larger size. … However, this is the opposite to what 8037’s actual beta value suggests, which is higher stock volatility relative to the market.

Simply Wall St -

Who Really Owns China Biotech Services Holdings Limited (HKG:8037)?

I am going to take a deep dive into China Biotech Services Holdings Limited’s (SEHK:8037) most recent ownership structure, not a frequent subject of discussion among individual investors. … See our latest analysis for China Biotech Services Holdings SEHK:8037 Ownership_summary Feb 21st 18 Insider Ownership I find insiders are another important group of stakeholders, who are directly involved in making key decisions related to the use of capital. … In general, this level of insider ownership has negatively affected underperforming (consistently low PE ratio) companies and positively affected the companies that outperform (consistently high PE ratio).

Simply Wall St -

Should You Worry About China Biotech Services Holdings Limited (HKG:8037) Cash Runway?

With a negative operating cash flow of -HK$10.70M, China Biotech Services Holdings is chipping away at its HK$64.61M cash reserves in order to run its business. … The measure of how fast China Biotech Services Holdings goes through its cash reserves over time is called the cash burn rate. … However, according to my analysis, if China Biotech Services Holdings continues to grow at this rate, it will burn through its cash reserves by the next 1 years, and may be coming to market again.

Simply Wall St -

What You Must Know About China Biotech Services Holdings Limited's (HKG:8037) Financial Strength

Moving onto cash from operations, its operating cash flow is not yet significant enough to calculate a meaningful cash-to-debt ratio, indicating that operational efficiency is something we’d need to take a look at. … SEHK:8037 Historical Debt Jan 21st 18 Can 8037 service its debt comfortably? … Investors' risk associated with debt is virtually non-existent with 8037, and the company has plenty of headroom and ability to raise debt should it need to in the future.Next Steps: 8037’s cash flow coverage indicates it could improve its operating efficiency in order to meet demand for debt repayments should unforeseen events arise.

Simply Wall St -

Interested In China Biotech Services Holdings Limited (HKG:8037)? Here's What Its Recent Performance Looks Like

View our latest analysis for China Biotech Services Holdings Did 8037's recent earnings growth beat the long-term trend and the industry? … For China Biotech Services Holdings, its latest earnings is -HK$48.2M, which, against the prior year's figure, has become less negative. … This means that, despite the fact that China Biotech Services Holdings is presently unprofitable, it may have been aided by industry tailwinds, moving earnings into a more favorable position.What does this mean?

Simply Wall St -

Company Info

Description

China Biotech Services Holdings Limited, an investment holding company, provides medical laboratory testing and health check services. It operates through four segments: Pharmaceutical Products, Medical and Health Related Services, Securities, and Others. The company also engages in the research, development, manufacture, sale, and distribution of health related and pharmaceutical products; trading of securities; and provision of research and development services, as well as in the money lending business. In addition, it markets and sells health supplements, Chinese medicines, slimming pills, and beauty products; and trades in pharmaceutical intermediates. Further, the company provides molecular diagnostic test and genetic investigation, and property investment services. It has operations primarily in the People’s Republic of China. China Biotech Services Holdings Limited has a strategic cooperation agreement with the Nanjing Medical University. The company was formerly known as Rui Kang Pharmaceutical Group Investments Limited and changed its name to China Biotech Services Holdings Limited in November 2017. China Biotech Services Holdings Limited was founded in 1996 and is headquartered in Causeway Bay, Hong Kong.

Details
Name: China Biotech Services Holdings Limited
8037
Exchange: SEHK
Founded: 1996
HK$1,230,193,310
968,656,150
Website: http://www.cbshhk.com
Address: China Biotech Services Holdings Limited
Sino Plaza,
Room 1904-5A,
Causeway Bay,
Hong Kong
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SEHK 8037 Ordinary Shares The Stock Exchange of Hong Kong Ltd. HK HKD 26. Jan 2005
Number of employees
Current staff
Staff numbers
125
China Biotech Services Holdings employees.
Industry
Health Care Services
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/16 12:44
End of day share price update: 2019/06/14 00:00
Last estimates confirmation: 2018/03/19
Last earnings filing: 2019/05/14
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.